Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.
Kodandaram Pillarisetti, Danlin Yang, Leopoldo Luistro...
https://pubmed.ncbi.nlm.nih.gov/41100731/Actively Recruiting
Led by Janssen Research & Development, LLC · Updated on 2026-09-25
276
Participants Needed
16
Research Sites
25 weeks
Total Duration
Researchers are evaluating the safety, tolerability, and optimal dosing of JNJ-79635322 combined with daratumumab, with or without lenalidomide or pomalidomide, in participants with multiple myeloma, newly diagnosed amyloid light chain AL amyloidosis, and high-risk smoldering multiple myeloma. This phase 1b trial aims to find recommended phase 2 doses RP2Ds and schedules for these combination treatments to better understand their effects and safety profiles. Participants receive JNJ-79635322 subcutaneously combined with daratumumab also given subcutaneously and may also receive oral lenalidomide or pomalidomide depending on their disease status and prior treatments. The study has two parts Part 1 involves dose escalation and de-escalation to determine safe and effective dosing, while Part 2 involves dose expansion to further evaluate safety and tolerability at the chosen doses in specific disease subgroups. Throughout the study, participants are closely monitored with assessments including dose-limiting toxicity within 28 days, adverse events and laboratory abnormalities over more than three years, and various response rates. Blood levels of the drugs and immune response markers are also measured. The study tracks participants disease responses and drug pharmacokinetics to gather comprehensive safety and effectiveness data over an extended period.
CONDITIONS
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
S
Study Contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Janssen Research & Development, LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | JNJ-79635322 With Backbone Therapy (Trial Regimens) | Current Guideline-Based Induction Regimens |
|---|---|---|
| What it is | An investigational trispecific antibody (JNJ-79635322) given with daratumumab (with or without lenalidomide) or pomalidomide in adults with multiple myeloma or AL amyloidosis. Multiple sequential regimens are studied in defined patient groups. | Established induction, consolidation, or relapse regimens for myeloma or AL amyloidosis, typically including combinations of proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, and corticosteroids as recommended by current clinical guidelines. |
| Role in Trial/Practice | Studied as an investigational regimen for efficacy, safety, and dosage optimization in various patient populations across sequential cohorts. | Represents current standard clinical practice for induction, consolidation, or rescue therapy per guideline recommendations for eligible patients. |
| Primary use | To determine the safety, recommended dosing, and preliminary efficacy of JNJ-79635322 combinations in adults with active multiple myeloma (new or relapsed/refractory), newly diagnosed AL amyloidosis, or high-risk smoldering myeloma. | To control disease activity, reduce plasma cell burden, and improve overall survival and organ function in patients with myeloma or AL amyloidosis. |
| How it is given or performed | JNJ-79635322 is administered as a subcutaneous injection, with daratumumab also subcutaneous, and lenalidomide or pomalidomide orally, given in sequentially assigned regimens by eligibility cohort. | Standard regimens involve fixed cycles of subcutaneous or intravenous drugs (proteasome inhibitors, anti-CD38 antibodies) and oral immunomodulatory agents, usually in combination over several months as per guideline protocols. |
| Evidence status | Ongoing study; results for this regimen are not yet established. Early clinical and preclinical evidence supports continued investigation. | Multiple large trials and expert consensus support the efficacy of current regimens in improving response rates, progression-free survival, and, in appropriate patients, overall survival. |
| Important limitations | Limited patient outcome data; efficacy and safety profiles for this trispecific antibody regimen are not yet established outside clinical trials. Multiple regimens and disease settings studied may make direct comparison challenging. | Real-world outcomes may vary by eligibility, comorbidity, and access; some regimens may be limited by toxicity, patient age, or specific organ involvement. Direct cross-trial comparisons remain limited. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 28 days per dose-limiting toxicity period
Participants receive escalating doses of JNJ-79635322 combined with daratumumab, with or without lenalidomide or pomalidomide, to establish safe and effective dosing schedules based on study team evaluations.
Regular visits for safety monitoring during dose escalation
Duration - Up to 3 years and 3 months
Participants receive the recommended phase 2 doses of the combination treatments to further evaluate safety and tolerability in different disease subgroups.
Scheduled visits for ongoing safety and response assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
5
Have more questions? Get in touch with our team for quick support
Kodandaram Pillarisetti, Danlin Yang, Leopoldo Luistro...
https://pubmed.ncbi.nlm.nih.gov/41100731/Janssen Research & Development, LLC
Lead Sponsor